Clinical Trial Detail

NCT ID NCT02871791
Title Palbociclib With Everolimus + Exemestane In BC
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Exemestane + Palbociclib

Age Groups: senior adult

Additional content available in CKB BOOST